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Intestinal Transplantation for Patients With Short Gut Syndrome and 
Hypercoagulable States 
M. Giraldo, D. Martin, J. Colangelo, J. Bueno, J. Reyes, J.J. Fung, T.E. Starzl, and K. Abu-Elmagd 
I NTESTINAL transplantation has become a life-saving procedure for patients with irreversible intestinal failure 
who can no longer be maintained on total parenteral 
nutrition (TPN).I This is the first report to address the 
management policy and efficacy of intestinal transplanta-
tion as a rescue therapy for patients with intestinal failure 
and visceral vascular thrombosis. 
MATERIALS AND METHODS 
Between May 2.1990 and August 18. 1999. a total of DO patients 
received primary intestinal transplantation at our center. Fifty-five 
were adults and splanchnic vascular thrombosis was the cause of 
loss of the native intestine in 17 (31%). Of these 17 patients. 8 
(47%) received isolated intestine. and 9 (53%) received composite 
visceral grafts that contained liver (5 liveriintestine. 4 muItivis-
ceral). Twelve (71 %) recipients were male and five (29%) were 
female with a mean age of 37 :!: 13 years. The preoperative 
work-up included a full hypercoagulable laboratory profile and 
visceral angiography for all patients. The thrombosis was arterial in 
12 (70.5%). venous (portomesenteric) in 4 (23.5%). and combined 
in the remaining case (6%). Concomitant extensive central venous 
thrombosis was documented preoperatively in 8 (47%) patients. 
The etiology of vascular thrombosis was hypercoagulable state in 9 
(53%). TIP in I (5.8%), myeloproliferative disorder in I (5.8%). 
and undetermined in the remaining 6 (35%) patients. 
The hypercoagulable syndrome was due to isolated/combined 
deficiency of proteins C and S and antithrombin III in all 9 patients, 
with concomitant factor V mutation in 2 cases. Composite visceral 
grafts were given only to patients with combined liver and intestinal 
failure and/or total vascular occlusion of the splanchnic circulation. 
Anticoagulant therapy was continued postoperatively as a lifelong 
treatment for all patients with superior vena cava syndrome and 
those who were hypercoagulable and received isolated intestinal 
transplantation. The donor characteristics. full details of donor/ 
recipient operations. and perioperative management. including 
immunosuppressive protocol. have been described e1sewhere. I - 3 
RESULTS 
With a mean follow-up of 27 months (range 5 to 106). five 
of the composite allograft recipients died and two of the 
isolated intestinal recipients required graft enterectomy. 
with an overall patient and graft survival of 71 % and 59%. 
respectively. The causes of death were bacterial/fungal 
sepsis (n = 3), cytomegalovirus (CMV) pneumonia (n = I). 
and postoperative lymphoproliferative disorder (PTLD) 
(n = 1). The two enterectomies were performed 9 and 20 
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days after transplantation because of postoperative bacte-
rial pneumonia with subsequent withdrawal of immunosup-
pression (n = 1) and intractable rejection (n = 1). The first 
patient died 21 months after graft enterectomy due to 
TPN-induced liver failure and the second is currently alive 
on TPN therapy. None of the isolated or composite visceral 
allografts were lost due to vascular thrombosis. All current 
survivors with graft in place (n = to) are completely off 
TPN with full enteric nutritional autonomy. 
The serum levels of proteins C and S and antithrombin 
III were normalized within the first week after transplanta-
tion in all of the nine recipients with preoperative hyperco-
agulable syndrome who received a liver as part of their 
composite visceral allograft. Unexpectedly. two of these 
recipients continued to experience recurrent episodes of 
venous thrombosis of their native vessels requiring prompt 
reinstitution of lifelong anticoagulant therapy. 
DISCUSSION 
Visceral vascular thrombosis was the common cause of 
irreversible intestinal failure in adult patients who received 
intestinal transplantation at our center. The diagnosis and 
etiology of the hypercoagulable state was achieved with 
certainty in more than half of the cases because of the 
recent development and availability of new hematologic, 
molecular diagnostic. and genetic tests.4 
Despite replacement of the native liver and subsequent 
correction of the underlying inborn metabolic errors. two of 
our composite visceral recipients continued to develop 
recurrent thrombosis of their native vessels. One possible 
explanation is the coexistence of extrahepatic hereditary 
defect at the endothelial level. Therefore, it has been our 
current policy to anticoagulate all of these patients for a 
minimum of 6 months postoperatively. 
In this study. five hypercoagulable patients with chronic 
intestinal failure and reversible TPN-induced liver damage 
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received intestinal transplantation without liver replace-
ment. None of these patients developed recurrent vascular 
thrombosis with postoperative anticoagulant therapy. In 
conclusion, visceral vascular thrombosis is a common indi-
cation for intestinal transplantation among adult patients. 
The diagnosis of a hypercoagulable state does not indicate 
replacement of an adequately functioning native liver but 
mandates lifelong anticoagulant therapy, particularly after 
isolated intestinal transplantation. 
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